FindTrial
Sign In

AIDSVAX B/E

BIOLOGICAL6 trials

Sponsors

U.S. Army Medical Research and Development Command, HIV Vaccine Trials Network, EuroVacc Foundation, Emergent BioSolutions

Conditions

HIV InfectionHIV InfectionsHIV VaccineHIV/AIDSHealthy Volunteer

Phase 1

Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults
CompletedNCT02109354
HIV Vaccine Trials NetworkHIV Infection
Start: 2013-06-18End: 2015-02-02Updated: 2019-06-21
Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS
CompletedNCT02376582
EuroVacc FoundationHIV/AIDS
Start: 2014-09-30End: 2016-01-31Updated: 2016-01-22
Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults
TerminatedNCT02771730
Emergent BioSolutionsHealthy Volunteer, HIV Vaccine
Start: 2015-03-31End: 2017-02-28Updated: 2024-03-18

Phase 2

Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144
NCT01435135
U.S. Army Medical Research and Development CommandHIV Infections
Start: 2012-04-30End: 2021-07-31Target: 162Updated: 2020-11-03
Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E
NCT01931358
U.S. Army Medical Research and Development CommandHIV Infections
Start: 2013-09-24End: 2021-12-31Target: 360Updated: 2021-03-26
Study of Immune Responses Induced by a HIV Vaccine
NCT01933685
U.S. Army Medical Research and Development CommandHIV Infections
Start: 2014-07-03End: 2020-05-31Target: 40Updated: 2019-09-19

Related Papers

A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials
Emerging Microbes & Infections2025-04-071 citations
The Question of HIV Vaccine: Why Is a Solution Not Yet Available?
Journal of Immunology Research2024-01-0112 citations
Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability
AIDS2023-06-0113 citations
Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response
PLoS Pathogens2023-05-317 citations
Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
2020-02-0638 citations
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.
2020-01-3016 citations
Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations
PLoS ONE2018-04-2717 citations
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial
PLoS Pathogens2017-02-2448 citations
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial
The Journal of Infectious Diseases2017-02-1770 citations
Uptake of Genital Mucosal Sampling in HVTN 097, a Phase 1b HIV Vaccine Trial in South Africa
PLoS ONE2014-11-179 citations